https://www.zacks.com/stock/news/2272792/why-cardinal-health-cah-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2272792
May 13, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zc:4298004719629792987
0
https://www.zacks.com/stock/news/2267290/compared-to-estimates-cardinal-cah-q3-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2267290
May 02, 2024 - The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zc:-5862980621005191549
0
https://www.zacks.com/stock/news/2266269/what-s-in-store-for-these-5-medical-device-stocks-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2266269
May 01, 2024 - Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.
zc:1844230321364240786
0
https://www.zacks.com/stock/news/2264353/what-s-in-store-for-cardinal-health-cah-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264353
Apr 29, 2024 - Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
zc:-158622387292231846
0
https://www.zacks.com/stock/news/2263589/factors-setting-the-tone-for-lantheus-lnth-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2263589
Apr 26, 2024 - Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
zc:-5758547865263595747
0
https://www.zacks.com/stock/news/2263563/here-s-what-you-should-know-about-ebay-ahead-of-q1-earnings?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2263563
Apr 26, 2024 - EBAY's first-quarter 2024 performance will likely reflect strength across its advertising business amid softness in its active buyer base.
zc:954390432984047453
0
https://www.zacks.com/stock/news/2263462/3-medical-products-stocks-set-to-beat-this-earnings-season?cid=CS-ZC-FT-earnings_esp-2263462
Apr 26, 2024 - Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
zc:-4677915270669463577
0
https://www.zacks.com/stock/news/2263271/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2263271
Apr 26, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zc:3524929706424642660
0
https://www.zacks.com/stock/news/2262641/etsy-gears-up-to-report-q1-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2262641
Apr 25, 2024 - ETSY's first-quarter 2024 earnings are likely to have gained from growing momentum among active buyers and active sellers.
zc:-2507821281549391752
0
https://seekingalpha.com/news/4093768-neurocrine-launches-cah-community-website-ahead-of-fda-filing?source=feed_sector_healthcare
Apr 24, 2024 - Neurocrine (NBIX), which has developed a drug for congenital adrenal hyperplasia, has launched a new interactive website to support patients with the condition. Read more here.
0
sa:-3211667522432803895
0